Lindén C, Nuija E, Alm A
Department of Ophthalmology, Umeå University, Sweden.
Br J Ophthalmol. 1997 May;81(5):370-2. doi: 10.1136/bjo.81.5.370.
To evaluate whether long-term treatment with the prostaglandin analogue latanoprost has a deleterious effect on the blood-aqueous barrier (BAB) and to determine the duration of the effect on intraocular pressure (IOP) after withdrawal of treatment.
Patients with ocular hypertension or glaucoma were topically treated with latanoprost 50 micrograms/ml once daily for 6-12 months. In 26 patients IOP was followed for 14 days after withdrawal of treatment. Aqueous flare was measured with a laser flare meter during 6-12 months' treatment in 16 patients.
On the last day of treatment IOP was 6.9 mm Hg (95% CI 5.3-8.5) lower than before treatment. It increased slowly during the follow up period but was still 1.3 mm Hg (95% CI 0.2-2.5) lower than pretreatment IOP 14 days after cessation of treatment. No change in aqueous flare was seen throughout the study.
Latanoprost has no clinically significant effect on the permeability of the BAB and IOP will return to pretreatment levels within a few weeks, indicating that latanoprost is safe for long-term treatment.
评估前列腺素类似物拉坦前列素的长期治疗是否对血-房水屏障(BAB)有不良影响,并确定停药后对眼压(IOP)影响的持续时间。
高眼压症或青光眼患者局部应用50微克/毫升拉坦前列素,每日一次,持续6 - 12个月。26例患者在停药后随访14天观察眼压。16例患者在6 - 12个月治疗期间用激光散射仪测量房水闪光。
治疗最后一天眼压比治疗前低6.9毫米汞柱(95%可信区间5.3 - 8.5)。随访期间眼压缓慢上升,但停药14天后仍比治疗前眼压低1.3毫米汞柱(95%可信区间0.2 - 2.5)。整个研究期间房水闪光未见变化。
拉坦前列素对血-房水屏障的通透性无临床显著影响,眼压在几周内会恢复到治疗前水平,表明拉坦前列素长期治疗是安全的。